Why the study?
Does ethanolic extract of Scleria lithosperma prevent doxorubicin-induced cardiotoxicity in Wistar albino rats?
Does ethanolic extract of Scleria lithosperma prevent doxorubicin-induced cardiotoxicity in Wistar albino rats?
This preclinical study outlines a methodology to evaluate the potential cardioprotective effects of Scleria lithosperma extract against doxorubicin-induced cardiotoxicity in a rat model.
Answers are grounded in this paper and cite their sources.
Outlines preclinical methodology for testing Scleria lithosperma cardioprotection; hypothesis-generating and leaves open any clinical translation.
The present study was designed to evaluate the protective effects of ethanolic extract of whole plant of Scleria lithosperma (EEWSL) against doxorubicin-induced cardiotoxicity in rats. Methodology: EEWSL was orally administrated in two different doses (250 mg/kg/day and 500 mg/kg/day) to wistar albino rats for 28 days and then intoxicated with doxorubicin (20 mg/kg) by intraperitoneal injection to induce myocardial toxicity. Lipid profile (Total cholesterol (TC), Triglyceride (TG), Low Density Lipoprotein-cholesterol (LDL-C) and High Density Lipoprotein-cholesterol (HDL-C)), antioxidant marker enzymes (Cardiac superoxide dismutase, Cardiac catalase activity, Glutathione reductase activity) and liver diagnostic marker enzymes (SALT, SAST, Creatine phosphokinase, Lactate dehydrogenase) were measured at the end of experimental period. Histopathological changes of heart were observed with optical microscopy.
No takes yet. Share an insight, caveat, or question.
Karunasree et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: